CD44 and familial pancreatic carcinoma: Similar to our results, Tajima et al. [10] showed the frequencies of CD44- positive cases were increased after gemcitabine-based neoadjuvant chemotherapy and concluded CD44- positive cells were chemoresistant in pancreatic cancer.